Background Intratumoral chemotherapy (ITC) has been used by many groups; the combination of heat and cytotoxic drugs increases the ability to destroy the malignant cells. The aim of this study was to assess the efficacy and safety of percutaneous injection of hyperthermic chemotherapy in conjunction with systemic chemotherapy as a palliative management of peripheral inoperable non-small cell lung cancer (NSCLC) compared to conventional systemic chemotherapy. Results There was a statistically significant improvement in quality of life score in group A and B, but deterioration in group C after 6 months. As regards radiology, after 6 months in group A, one patient (10%) showed complete response, 6 patients (60%) showed partial response, one patient (10%) stable response, and two patients (20%) showed progression; in group B, 6 patients (60%) showed partial response, two patients (20%) showed stable response, and two patients (20%) showed progression; and in group C, 7 patients (70%) showed progression, two patients (20%) showed partial response, and one patient (10%) showed stable response. There were few controllable complications. Median survival in group A was 16 months, in group B was 15 months, and in group C was 8 months. Conclusion Intratumoral hyperthermic chemotherapy is a promising, effective, harmless palliative therapy for inoperable peripheral NSCLC.

Background: Antimalarial drugs including Hydroxychloroquine (HCQ) and chloroquine have been demonstrated to be associated with anti-inflammatory actions in different connective tissue diseases (CTD) as rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). One of the points of interest was the emergent antiviral effect of these drugs against Covid-19 infection. However, this antiviral effect is still debatable. Objective: The objective was to study HCQ effects on the severity and outcome of COVID-19 infection in patients with RA and SLE. Patients and Methods: A total of 94 cases diagnosed as RA and SLE with COVID-19 infection were comprised in the study and were categorized into 2 groups: the first group included patients who were receiving HCQ treatment before infection, and the second group included patients who were not receiving HCQ before. Clinical, laboratory, and radiological findings as well as the outcome of patients were assessed to compare the severity of COVID-19 infection in both groups. Results: Demographic data showed higher female predominance. Fever, cough, rhinorrhea, and myalgia were observed in both groups with no significant variation except for rhinorrhea. D-dimer was significantly increased in the first group. Decreased oxygen saturation, need for mechanical ventilation, radiological changes suggestive of COVID-19 infection, and acute kidney injury (AKI) were more observed in the HCQ group with statistical significance. Conclusion: HCQ administration was not associated with less severe infection or better outcomes in RA and SLE patients infected with COVID-19.

Pleural lipoma is an extremely rare benign tumor. A lesion homogeneity with smooth borders is a suggestive criterion of lipoma in the chest radiology. Tissue biopsy is usually required for the diagnosis and exclusion of liposarcoma. In this case report, we described a female patient diagnosed with a pleural lipoma which was discovered accidentally during a metastatic work up of a previously diagnosed squamous cell carcinoma in the left ala nasi. The diagnosis of the pleural lipoma was histopathologically confirmed with tru cut biopsy.

No abstract

No abstract